Edition:
United Kingdom

Mabion SA (MABP.WA)

MABP.WA on Warsaw Stock Exchange

75.40PLN
26 Jun 2019
Change (% chg)

-- (--)
Prev Close
75.40zł
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,764
52-wk High
124.00zł
52-wk Low
66.00zł

Latest Key Developments (Source: Significant Developments)

Mabion Q1 Net Loss Widens To 15.0 Mln Zlotys
Thursday, 16 May 2019 

May 17 (Reuters) - MABION SA ::REPORTED ON THURSDAY Q1 NET LOSS OF 15.0 MILLION ZLOTYS VERSUS LOSS OF 14.3 MILLION ZLOTYS YEAR AGO.Q1 OPERATING LOSS OF 14.5 MILLION ZLOTYS VERSUS LOSS OF 14.1 MILLION ZLOTYS YEAR AGO.  Full Article

Artur Chabowski Steps Down As CEO of Mabion
Thursday, 25 Apr 2019 

April 25 (Reuters) - Mabion SA ::CEO ARTUR CHABOWSKI STEPS DOWN AS OF JUNE 30.  Full Article

Mabion Updates Strategy Of Medicinal Product Development
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Mabion SA ::UPDATES ITS STRATEGY OF MEDICINAL PRODUCT DEVELOPMENT.PLANS TO LAUNCH RESEARCH AND DEVELOPMENT WORKS ON BIOSIMILAR DRUGS IN FIELD OF AUTOIMMUNITY, METABOLIC DISEASES AND ONCOLOGY.  Full Article

Mabion Q3 Net Loss Narrows To 11.1 Mln Zlotys
Thursday, 15 Nov 2018 

Nov 16 (Reuters) - MABION SA ::SAID ON THURSDAY Q3 NET LOSS WAS AT 11.1 MLN ZLOTYS VS LOSS OF 13.2 MLN ZLOTYS YR AGO.Q3 OPERATING LOSS 11.8 MLN ZLOTYS VS LOSS OF 13.2 MLN ZLOTYS YR AGO.  Full Article

Mabion Files Second Patent Application
Friday, 26 Oct 2018 

Oct 29 (Reuters) - MABION SA ::SAID ON FRIDAY IT FILED A SECOND PATENT APPLICATION FOR ITS INVENTION FROM AREA OF ​​APPLICATION OF MABIONCD20 IN TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS 'LOW AGGREGATE ANTI CD20 LIGAND FORMULATION'.IN DEC. 2017 CO FILED FOR PATENT FOR ITS INVENTION 'COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND' nFWN1O50T6.  Full Article

Mabion Gets USD 5 Mln Milestone Payment From Mylan Ireland
Monday, 27 Aug 2018 

Aug 27 (Reuters) - MABION SA ::RECEIVES USD 5 MILLION MILESTONE PAYMENT FROM MYLAN IRELAND, FOLLOWING IMPLEMENTATION OF KEY STAGE IN COOPERATION AGREEMENT WITH MYLAN IRELAND.SAYS ACCORDING TO COOPERATION AGREEMENT IT IS ENTITLED TO GET UP TO ADDITIONAL USD 30 MILLION.FUTURE PAYMENTS DEPEND ON APPROVAL AND PROGRESS IN COMERCIALISATION OF MABIONCD20 DRUG.  Full Article

Mabion Receives Summary Of US FDA After Biological Development Meeting
Thursday, 28 Jun 2018 

June 28 (Reuters) - Mabion SA ::RECEIVES SUMMARY OF US FOOD AND DRUG ADMINISTRATION (FDA) AFTER A TYPE B BIOLOGICAL DEVELOPMENT (BPD) MEETING.  Full Article

Mabion Q1 Net Loss Widens To 14.3 Million Zlotys
Wednesday, 30 May 2018 

May 30 (Reuters) - MABION SA ::Q1 NET LOSS 14.3 MILLION ZLOTYS VERSUS LOSS OF 12.9 MILLION ZLOTYS YEAR AGO.  Full Article

Mabion To Replace GetBack In mWIG40
Monday, 7 May 2018 

May 7 (Reuters) - WARSAW STOCK EXCHANGE (WSE)::GETBACK SA <<>> WILL BE REPLACED IN THE WARSAW STOCK EXCHANGE'S MWIG40 INDEX .MWIG40 BY MABION SA <<>> AFTER THE SESSION ON MAY 8, WSE SAID IN A STATEMENT ON MAY 4.MABION'S PLACE IN SWIG80 INDEX .SWIG80 WILL BE TAKEN BY KRUSZWICA <<>>.GETBACK APPLIED FOR ACCELERATED ARRANGEMENT PROCEEDINGS AS PART OF ITS RESTRUCTURING ON MAY 2 nL8N1SB10H.  Full Article

Mabion To Increase Share Capital Through Private Share Issue
Wednesday, 18 Apr 2018 

April 18 (Reuters) - MABION SA ::SHAREHOLDERS AGREE ON SHARE CAPITAL INCREASE THROUGH ISSUE OF 1.9 MILLION OF SERIES P SHARES.SERIES P SHARE TO BE ISSUED VIA PRIVATE SHARE ISSUE WITHOUT PREEMPTIVE RIGHTS.SERIES P SHARE ISSUE PRICE SET AT 91 ZLOTY PER SHARE.THE MANAGEMENT BOARD HAS ALSO BEEN AUTHORIZED TO SETTLE THE ALLOTMENT OF SHARES THROUGH LOAN SETTLEMENT WITH SHAREHOLDER, TWITI INVESTMENTS LTD .  Full Article

BRIEF-Mabion Q1 Net Loss Widens To 15.0 Mln Zlotys

* REPORTED ON THURSDAY Q1 NET LOSS OF 15.0 MILLION ZLOTYS VERSUS LOSS OF 14.3 MILLION ZLOTYS YEAR AGO